Locke JM - Search Results

1

Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles.

Stutchbury TK, Vine KL, Locke JM, Chrisp JS, Bremner JB, Clingan PR, Ranson M. Stutchbury TK, et al. Among authors: locke jm. Anticancer Drugs. 2011 Jan;22(1):24-34. doi: 10.1097/CAD.0b013e32833f6d22. Anticancer Drugs. 2011. PMID: 20881836

2

Development and assessment of novel all-in-one parenteral formulations with integrated anticoagulant properties for the concomitant delivery of 5-fluorouracil and calcium folinate.

Locke JM, Stutchbury TK, Vine KL, Gamble AB, Clingan PR, Bremner JB, Ranson M. Locke JM, et al. Anticancer Drugs. 2009 Oct;20(9):822-31. doi: 10.1097/CAD.0b013e32832fd78e. Anticancer Drugs. 2009. PMID: 19606016

3

The antiangiogenic properties of sulfated β-cyclodextrins in anticancer formulations incorporating 5-fluorouracil.

Watson CA, Vine KL, Locke JM, Bezos A, Parish CR, Ranson M. Watson CA, et al. Among authors: locke jm. Anticancer Drugs. 2013 Aug;24(7):704-14. doi: 10.1097/CAD.0b013e3283626fdd. Anticancer Drugs. 2013. PMID: 23695012

4

Cytotoxic and anticancer activities of isatin and its derivatives: a comprehensive review from 2000-2008.

Vine KL, Matesic L, Locke JM, Ranson M, Skropeta D. Vine KL, et al. Among authors: locke jm. Anticancer Agents Med Chem. 2009 May;9(4):397-414. doi: 10.2174/1871520610909040397. Anticancer Agents Med Chem. 2009. PMID: 19442041 Review.

5

Targeting urokinase and the transferrin receptor with novel, anti-mitotic N-alkylisatin cytotoxin conjugates causes selective cancer cell death and reduces tumor growth.

Vine KL, Indira Chandran V, Locke JM, Matesic L, Lee J, Skropeta D, Bremner JB, Ranson M. Vine KL, et al. Among authors: locke jm. Curr Cancer Drug Targets. 2012 Jan;12(1):64-73. doi: 10.2174/156800912798888983. Curr Cancer Drug Targets. 2012. PMID: 22111834

6

In vitro cytotoxicity evaluation of some substituted isatin derivatives.

Vine KL, Locke JM, Ranson M, Benkendorff K, Pyne SG, Bremner JB. Vine KL, et al. Among authors: locke jm. Bioorg Med Chem. 2007 Jan 15;15(2):931-8. doi: 10.1016/j.bmc.2006.10.035. Epub 2006 Oct 20. Bioorg Med Chem. 2007. PMID: 17088067

7

An investigation into the cytotoxicity and mode of action of some novel N-alkyl-substituted isatins.

Vine KL, Locke JM, Ranson M, Pyne SG, Bremner JB. Vine KL, et al. Among authors: locke jm. J Med Chem. 2007 Oct 18;50(21):5109-17. doi: 10.1021/jm0704189. Epub 2007 Sep 21. J Med Chem. 2007. PMID: 17887662

8

N-phenethyl and N-naphthylmethyl isatins and analogues as in vitro cytotoxic agents.

Matesic L, Locke JM, Bremner JB, Pyne SG, Skropeta D, Ranson M, Vine KL. Matesic L, et al. Among authors: locke jm. Bioorg Med Chem. 2008 Mar 15;16(6):3118-24. doi: 10.1016/j.bmc.2007.12.026. Epub 2008 Jan 7. Bioorg Med Chem. 2008. PMID: 18182300

9

Selective targeting of 2'-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro.

Vine KL, Locke JM, Bremner JB, Pyne SG, Ranson M. Vine KL, et al. Among authors: locke jm. Bioorg Med Chem Lett. 2010 May 1;20(9):2908-11. doi: 10.1016/j.bmcl.2010.03.029. Epub 2010 Mar 9. Bioorg Med Chem Lett. 2010. PMID: 20363130

10

Synthesis and hydrolytic evaluation of acid-labile imine-linked cytotoxic isatin model systems.

Matesic L, Locke JM, Vine KL, Ranson M, Bremner JB, Skropeta D. Matesic L, et al. Among authors: locke jm. Bioorg Med Chem. 2011 Mar 1;19(5):1771-8. doi: 10.1016/j.bmc.2011.01.015. Epub 2011 Jan 14. Bioorg Med Chem. 2011. PMID: 21306903

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters